{"ticker": {"uuid": "2b99c525-a76a-4b04-bbcb-e6bb713af621", "symbol": "NAGE", "name": "Niagen Bioscience, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Niagen Bioscience (NAGE) to Announce Q2 Financial Results on August 4, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPRTRQdHpHVncyZHdDbUtpLW1NS09BRk40RDl4anBQRUh0OU1OUlZwSWVDN1pFWlF4c0d5M1MtNG1wc0pnUE9pYm5icUFULXJ3RHhWcVY1d2dPdUEzS21EUGxQSVhsOGNEVVFFZFA4SWpwTUVvWGd1cU9CYlMxdkdBalA2S09mb0RkNmIyamliNEk5aDl0X3g4QjNQQV9nemFoY2FuazVLMEhVSVlNQ1JHMQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-21T14:47:43+00:00", "published_display": "21 Jul 2026 14:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience to report Q2 2026 results on August 4", "summary": "Niagen Bioscience, Inc. is scheduled to announce its financial results for the second quarter ending June 30, 2026, on Tuesday, August 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a business update for the company, ", "url": "https://scanx.trade/stock-market-news/companies/niagen-bioscience-to-report-q2-2026-results-on-august-4/46189098", "source_name": "scanx.trade", "published_at": "2026-07-21T14:40:21", "published_display": "21 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Appoints Dr. Abhijit Kale to Lead Global NAD+ Research", "summary": "Niagen Bioscience has appointed Dr. Abhijit Kale as Senior Director of Global External Research to lead its Niagen Research Program. Dr. Kale, with over a decade of experience in aging biology and translational science, will oversee global academic and clinical research collabora", "url": "https://www.latimes.com/b2b/health-life-science/story/2026-07-21/niagen-bioscience-appoints-abhijit-kale", "source_name": "Los Angeles Times", "published_at": "2026-07-21T14:40:20", "published_display": "21 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/niagen-bioscience-report-second-quarter-123200156.html", "source_name": "Business Wire", "published_at": "2026-07-21T12:32:00+00:00", "published_display": "21 Jul 2026 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SteelPeak Wealth LLC Makes New Investment in Niagen Bioscience, Inc. $NAGE", "summary": "SteelPeak Wealth LLC has made a new investment in Niagen Bioscience, Inc. (NASDAQ:NAGE) during the first quarter, acquiring 3,373,000 shares valued at approximately $14.88 million. This new stake represents about 4.24% of the company. Other institutional investors have also adjus", "url": "https://www.marketbeat.com/instant-alerts/filing-steelpeak-wealth-llc-makes-new-investment-in-niagen-bioscience-inc-nage-2026-07-17/", "source_name": "MarketBeat", "published_at": "2026-07-17T10:09:54", "published_display": "17 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research", "summary": "Niagen Bioscience, Inc. has appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will lead the Global Niagen Research Program, overseeing collaborations and shaping the scientific research strategy related to NAD+ biolog", "url": "https://www.businesswire.com/news/home/20260716002772/en/Niagen-Bioscience-Appoints-Abhijit-Kale-Ph.D.-as-Senior-Director-of-Global-External-Research", "source_name": "Business Wire", "published_at": "2026-07-16T21:40:31", "published_display": "16 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)", "summary": "Niagen Bioscience has received both U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168, a novel small molecule therapy for Ataxia Telangiectasia (A-T). These designations highlight the significant", "url": "https://www.businesswire.com/news/home/20260713674314/en/Niagen-Bioscience-Receives-Exclusive-U.S.-FDA-Rare-Pediatric-Disease-RPD-Designation-and-European-Medicines-Agency-Orphan-Medicinal-Product-Designation-OMPD-for-NB4168-for-the-Treatment-of-Ataxia-Telangiectasia-A-T", "source_name": "Business Wire", "published_at": "2026-07-13T12:41:34", "published_display": "13 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience receives FDA, EMA designations for rare disease drug", "summary": "Niagen Bioscience has received Rare Pediatric Disease Designation from the FDA and Orphan Medicinal Product Designation from the EMA for its drug candidate NB4168, which treats Ataxia Telangiectasia. This rare genetic disease currently has no FDA-approved therapies. Despite a 70%", "url": "https://www.investing.com/news/company-news/niagen-bioscience-receives-fda-ema-designations-for-rare-disease-drug-93CH-4788514", "source_name": "Investing.com", "published_at": "2026-07-13T12:41:34", "published_display": "13 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Niagen Bioscience (NAGE) Stock Looks Reasonable On Earnings Yet Weak On Broader Checks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T23:50:14+00:00", "published_display": "10 Jul 2026 23:50", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience files prospectus to offer common stock up to $50M", "summary": "Niagen Bioscience has filed a prospectus with the SEC to offer and sell up to $50 million in common stock. This move is part of the company's financial strategy to raise capital for future growth, operations, and expansion initiatives. The prospectus details the offering type and", "url": "https://scanx.trade/stock-market-news/ipo/niagen-bioscience-files-prospectus-to-offer-common-stock-up-to-50m/45270726", "source_name": "scanx.trade", "published_at": "2026-07-10T23:40:44", "published_display": "10 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Niagen Bioscience Inc For: 10 July By Investing.com", "summary": "This article reports on the filing of Form 424B5 by Niagen Bioscience Inc. on July 10, 2026. It mentions the company's stock symbol NAGE, which saw a -2.87% change. The content primarily consists of a single sentence announcing the filing, surrounded by numerous navigational link", "url": "https://za.investing.com/news/stock-market-news/form-424b5-niagen-bioscience-inc-for-10-july-93CH-4365025", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T23:10:00", "published_display": "10 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) CFO acquires stock through employee purchase plan", "summary": "Niagen Bioscience's CFO, Pamir Ozan, acquired 4,255 shares of common stock at $2.71 per share through the company's Employee Stock Purchase Plan. This transaction increased Ozan's direct holdings to approximately 11,627 shares, with an additional 2,220 shares indirectly held by t", "url": "https://www.stocktitan.net/sec-filings/NAGE/form-4-niagen-bioscience-inc-insider-trading-activity-4cc4604af45f.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:09:33", "published_display": "09 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital", "summary": "Freedom Capital has upgraded Niagen Bioscience (NASDAQ:NAGE) to a \"strong-buy\" rating, contributing to a mixed analyst sentiment that still results in an average \"Buy\" rating and a consensus price target of $10.50. The stock recently traded down to $3.37, below its moving average", "url": "https://www.marketbeat.com/instant-alerts/niagen-bioscience-nasdaqnage-stock-rating-upgraded-by-freedom-capital-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T16:11:47", "published_display": "09 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026", "summary": "Niagen Bioscience CEO Rob Fried will participate in a virtual fireside chat on July 15, 2026, to discuss the company's recently launched pharmaceutical program for rare genetic diseases and aging-related disorders. The chat will also cover Niagen Bioscience's leadership in NAD+ s", "url": "https://www.businesswire.com/news/home/20260709834448/en/Niagen-Bioscience-CEO-Rob-Fried-to-Participate-in-Virtual-Fireside-Chat-to-Discuss-Pharmaceutical-Strategy-on-July-15-2026", "source_name": "Business Wire", "published_at": "2026-07-09T12:41:10", "published_display": "09 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Niagen Bioscience Inc For: 8 July By Investing.com", "summary": "This article provides details about a Form 4 filing for Niagen Bioscience Inc. on July 8. It indicates that the document is published by Investing.com and was released on July 8, 2026, at 05:22 p.m. The core content highlights the Form 4 filing for NAGE, with a stock performance ", "url": "https://ca.investing.com/news/stock-market-news/form-4-niagen-bioscience-inc-for-8-july-93CH-4726115", "source_name": "Investing.com Canada", "published_at": "2026-07-08T21:40:30", "published_display": "08 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/niagen-bioscience-launches-program-develop-131759130.html", "source_name": "MT Newswires", "published_at": "2026-07-08T13:17:59+00:00", "published_display": "08 Jul 2026 13:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience launches drug candidate for rare disease", "summary": "Niagen Bioscience has announced the launch of NB4168, a drug candidate for Ataxia Telangiectasia (A-T), a rare genetic disease with no FDA-approved therapies. Despite a recent stock decline, the company shows solid fundamentals with a 64% gross profit margin and positive earnings", "url": "https://www.investing.com/news/company-news/niagen-bioscience-launches-drug-candidate-for-rare-disease-93CH-4781634", "source_name": "Investing.com", "published_at": "2026-07-08T13:39:19", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases", "summary": "Niagen Bioscience has launched a pharmaceutical program through its subsidiary, NAD Pharmaceuticals Corp., to develop therapies for accelerated aging and rare genetic diseases. The program's first drug candidate, NB4168, a proprietary NAD+ precursor derivative, will initially tar", "url": "https://www.businesswire.com/news/home/20260708248360/en/Niagen-Bioscience-Launches-Pharmaceutical-Program-for-Accelerated-Aging-and-Rare-Genetic-Diseases", "source_name": "Business Wire", "published_at": "2026-07-08T12:39:19", "published_display": "08 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) CEO adds 1,106 ESPP shares, holds 1.06M directly", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNbVJlRDQtdkZtRkEwMDlzYTNEall6LVNZMjRQYUtfN2ZOaXpOb3NFcVFGUDFOb096WWlOdl84MzJHQXk3Smk4aTc5b2ZhekRpZ1pIVXJPMU9mdU1jT0hlUlZBSFRQbF9FR0pzOHppMGZmdjB5WU1reVE0dWhFdjBvNk1qZjl1ZE45U3Y5MDZQaVFYdTViUXRVN1EyRUNieElRLU41R1g5THFDR2dKYVJaa1U2VlE1Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen pushes NAD+ science into drug development for rare disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNTWNfcWdVUHQ0SlhsZ3pMTWVVM0YySm8wdnVpZGk3aVpuZVdFZHhnQ3FaSmJGTzJKYjhYa1lYc1hfUVFWbVV3eXpDUWtBaTlOcGc0ektoS1RrcnVRbVM0MUZtaFZrVjlUdml0R3huaE5oVWZ2eDB5aDdpaV9LQmNrOXJnREFkY1lKNkNoTmJQdXpZRkIwTlNLUzdIMGxfRHZsTjBHazRaaEhJZkJlVUE2cDJvRHN2Zk8xZ2tYQw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Niagen Bioscience, Inc. \u2013 NASDAQ:NAGE", "summary": "The article title indicates a focus on the Enterprise Value to EBIT forward metric for Niagen Bioscience, Inc. (NASDAQ: NAGE). The content appears to be a stub or a section from a larger financial data platform, providing only the title and navigation/footer information without t", "url": "https://www.tradingview.com/symbols/NASDAQ-NAGE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T22:42:05", "published_display": "06 Jul 2026 22:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) SVP, General Counsel acquires 2,314 ESPP shares", "summary": "Niagen Bioscience's SVP and General Counsel, Carlos Luis Lopez, acquired 2,314 common shares at $2.71 each through the company's Employee Stock Purchase Plan (ESPP). This transaction, exempt under SEC Rules 16b-3(c) and 16b-3(d), increased his direct ownership to 4,565 shares. Th", "url": "https://www.stocktitan.net/sec-filings/NAGE/form-4-niagen-bioscience-inc-insider-trading-activity-6d5c51419df5.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:04", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freedom Broker initiates Niagen Bioscience stock coverage with buy rating", "summary": "Freedom Broker has initiated coverage on Niagen Bioscience Inc. (NASDAQ:NAGE) with a Buy rating and a $9.00 price target, highlighting significant upside potential given its current trading price of $3.49 against an analyst consensus of $10-$18. The firm's investment thesis is su", "url": "https://www.investing.com/news/analyst-ratings/freedom-broker-initiates-niagen-bioscience-stock-coverage-with-buy-rating-93CH-4777300", "source_name": "Investing.com", "published_at": "2026-07-06T20:12:15", "published_display": "06 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freedom Broker initiates Niagen Bioscience stock coverage with buy rating By Investing.com", "summary": "Freedom Broker has initiated coverage on Niagen Bioscience Inc. (NASDAQ:NAGE) with a Buy rating and a price target of $9.00, citing significant upside potential from its current trading price of $3.49. The firm's investment thesis is based on secular tailwinds in the longevity ec", "url": "https://ca.investing.com/news/stock-market-news/freedom-broker-initiates-niagen-bioscience-stock-coverage-with-buy-rating-93CH-4721491", "source_name": "Investing.com Canada", "published_at": "2026-07-06T19:42:05", "published_display": "06 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Implied Volatility Surging for Niagen Bioscience Stock Options", "summary": "Implied volatility for Niagen Bioscience (NAGE) stock options is surging, particularly for the August 21, 2026 $12.50 Call, indicating that the market expects significant price movement. Despite this, analysts currently rate NAGE as a Zacks Rank #3 (Hold), with recent downward re", "url": "https://www.tradingview.com/news/zacks:26468dc52094b:0-implied-volatility-surging-for-niagen-bioscience-stock-options/", "source_name": "TradingView", "published_at": "2026-07-06T15:41:32", "published_display": "06 Jul 2026 15:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAGE - Niagen Bioscience Inc Options", "summary": "This page provides a detailed financial overview of Niagen Bioscience Inc (NAGE), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key metrics such as P/E, EPS, insider and institutional ownership, profitabi", "url": "https://finviz.com/stock?t=NAGE&p=d&ty=oc&r=m6&e=2026-07-17&ov=list_date", "source_name": "Finviz", "published_at": "2026-07-05T17:41:32", "published_display": "05 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Niagen Bioscience, Inc (NAGE)", "summary": "This article analyzes the historical performance of investing $1,000 in Niagen Bioscience, Inc. (NAGE) over different periods. It provides an overview of Niagen Bioscience, detailing its focus on NAD+ science and healthy-aging research through patented ingredients like Niagen\u00ae, c", "url": "https://www.stocktitan.net/tools/stock-return-calculator/NAGE", "source_name": "Stock Titan", "published_at": "2026-07-05T05:42:05", "published_display": "05 Jul 2026 05:42", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Niagen Bioscience stock rating on patent ruling By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and an $11.00 price target for Niagen Bioscience (NASDAQ: NAGE) following a favorable patent ruling. The U.S. District Court for the District of Delaware upheld the enforceability of a patent related to crystalline nicotinamide riboside", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-niagen-bioscience-stock-rating-on-patent-ruling-93CH-4715938", "source_name": "Investing.com Canada", "published_at": "2026-07-01T11:39:37", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Niagen Bioscience Inc For: 29 June By Investing.com", "summary": "This article announces that Investing.com has published information regarding the Form S-3 filing by Niagen Bioscience Inc for June 29. The brief notice highlights the filing and its publication date. It also provides current stock market data for various indices, commodities, an", "url": "https://ng.investing.com/news/stock-market-news/form-s3-niagen-bioscience-inc-for-29-june-93CH-2577409", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T03:40:24", "published_display": "30 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Niagen Bioscience Inc For: 26 June By Investing.com", "summary": "This article provides an Investing.com report on the Form 4 filing for Niagen Bioscience Inc., dated June 26. It includes standard disclaimers about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing that the provided data may not be re", "url": "https://m.au.investing.com/news/stock-market-news/form-4-niagen-bioscience-inc-for-26-june-93CH-4507476?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-27T01:39:16", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) director granted 31,746 stock options at $3.45", "summary": "Niagen Bioscience (NAGE) director Patrick Kristin was granted 31,746 stock options with an exercise price of $3.45 per share. These options will vest 100% on June 24, 2027, and have an expiration date of June 23, 2036. This transaction is classified as an equity compensation awar", "url": "https://www.stocktitan.net/sec-filings/NAGE/form-4-niagen-bioscience-inc-insider-trading-activity-a9625be28c13.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:10:21", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Steven D. Rubin receives 31,746 Niagen Bioscience (NAGE) stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOb1hFeFlKakJnXzN5UmV3YS1zMGlCVEFCUks4NHpUVjkwUGdQSnJTVkhsbURWTGtCZDd6ZjNIVlM0UV8yaHlMNVNCZzVUeVQ0Wml3aV9nOEtydDRGdU1xZC1wRjF3Z2tqN0gxMjI4NlZFZzUySFVuNWppOVBaXy1vbXFVeFlyM0ViTTJzSXVwWVBsVUh4S3dlZV9xR193bWtiTm9hTEQ3Sm55ek5aTjc2eGowSFUzUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) director receives 31,746-share stock option grant at $3.45", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOTE5Rb1hCclZ4dFQ3SGxzbTkzMnNEVnBOTUhTVEpjaTBmaHpSNG02RkJkNjdVN2JVWHJLMzYydFhWMUFXVmczSkF3Ujh4NWFsNkRIbktqOTVsTVB6ZnhWLXBlelQ2V3J3TlVSM2Q3Vk9kazJJSTh4Ym5RVTQzeVcyVVJYUmhKbW5FejFOYTlRckZ2UEpQRy1WaDNpVEQyYl9nZnNFOGxrdFhMcVlrNXA3WDY0VFM5UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/niagen-bioscience-inc-nage-renames-182049027.html", "source_name": "Insider Monkey", "published_at": "2026-06-19T18:20:49+00:00", "published_display": "19 Jun 2026 18:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience And 2 Other Promising Penny Stocks To Watch", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNVjQzYU45Qnl0b3Nub2JOVy0wRmlaejRXNHFETTB2andLSjhhZzAteXAwaUJUenpjODVoMnBycGdaSW5yeWdxLUJPd185NTRGVGpXUkZUX1VWWVlJTkxZNDJWVTVCMHVjZTM0bFpkZkRiSlJXYUoxcnpqOV9KdWpHRy1FcTlzV0ZWMFlRd3lLeDluLXpfQTZIUDlmdjM4T3hfX0pmOXVXenctd1E?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Niagen's program backing 300+ NAD+ research collaborations", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOWUpvZzNwQUhJNnlQVGJCNU5tdl9DWDNOY2Z1M1pqTjZ0ZmNoR2IwMTUxMmFOWlc5NXF4R0lxN2FpdlJQRGR5TVhIVFhJQjk5cDk5RFJVQTFBMDF4d054NmlNU29BekVXQVRHeG9DNEdJVG50YnY1OHhlSTBuaWw4eTNiWjduNzV1S2RiMGZCWVdiZ2xWMFplU1lSUTg4Mkhrb25RdVUycER0TUxIRFhaa1Mtd0lMbHJIMGhveg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPcDM0YmxQaWdQTWhVbGtNWnFxZzZySl9mMG8yNDJ0bklZdUpud1E1cEZzZ24yanphcllacThQUEVuTVlhZVBjaDhSME1aSkhEX1ktbVRNYVR2bG4wdHpWTGxldXlIdVJmeWJpWEJmX0ZUYXlPMU5wTURObllDSXhqNzB4ZFFLczhaQ2VZczdBZURKQjNRSjZxMUtEWHM5ODdPRkJONQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYVlablRJTEw5Uy1DOW5pUjlzSkhqOEtESVYtZkxPRHktb2FoQU5KdDFkZVBIOUtJR3pfUUxpNFYwUjdEcURXWTlDNEJhdHBnamp1VFhvV1p4cUJYcWlFemVNblpsQzl5YzFRWFY2V3ZVbGRubEstbXN4d2k5eWs1aUxhekFqRW5wcWR0emh2b25qaVJhd0NnWmpJSlpuUmhlb2tFUGN4ODBfSEU?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQLVFZMkZkNVgwcmhXNXJkZFBzcDZOWVpKQ2pveTRabDJSX1Z5MWpFTzRYaFlISXJ6QjZVTWpUTi14OVYycVdGY3F0a2loUmctZTZwM2NKX0lsMDBjeFptenV5Nm4wQjVGckFPNlFLdGhWdk1aZkY3bmpQRjBfcS1xbWtYQ3ljRUcyejNVemZEQzFnOWRFT1lMVnRxNkJPamZuYm54SnF3?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcDExT0lHVnhRTjNQT0pGTWxLNHJXc1hzdjdHVVZ4NWp2TzZMWjhVeXhqY0loWHZyUW1STlh1X0w5Y3pwaVZkWnc5VXlfM0ZOOThJeko3cVJqaUFkWjRvRlRieVhyeS12Ym9HNVpYS0NKajAxcEwtNFZYZXBkSmVFbS0yc1FWUE5CRGp5Z2FQNVVGZzFOcGRnZXlZcVVTaXQ1OHhQR2RQb2pZcGZfRTRqSDVSM0xHNGhCWHphdHdwZ091WGNmWkkyVjVKOWdGQi16cWVqOTg5Uzkya2dIa3c?oc=5", "source_name": "Business Wire", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZWkwc2s3RTBzemNHT3VmakR3Ukdwd1FQRlhpU2M2Y3B2RFVsbHJnV0s2dTJkQ2x2WjA5WXFwblpkS1RzYjN4U3UzSVNGV2JGTlZGUjI4RGtBLUxQNTZaMGdFNkt5V0lrd05tekpzMVdLQ191bHRfYkoxR3ZMNzBwOGZla2w1dGRYVHU4RmlJaE9wUHVlMldyNFFGM2VPaWdjelFicVB1XzM?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Inc. (NAGE): Among the 12 Cheap Penny Stocks to Invest In Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPZFdZVkc0NzlhRjQ5TG9Ma0xJN0VxTW1sRG9pdzFXNjR2a3Zid3hsRHdIZTlYalBnU0tTalBUOU9WSTFwSTFDNWVMdXpiN3hseVg5dVQ3dkJLRjhLdlhNbTJGZ05TWm96OFJhUzlWMXdqcnRSUjJTSXpoVVMxZ2hNamRWLXhORlJBcThUUlZuX3EyN21Dd1dxWWV4SFBvQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Niagen Bioscience (NAGE) Story Is Shifting Around Price Targets And Injectables Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxORUFuOHdjVDU1cklMb3BWTGNDd3hqQnp5YURjVmVOMXlQVm14N1U5cldfdUt1MEtTVTZBcTNBZHBqS0JQdnp5UVNicUtXWW1aQmtVb2RGaVpQUEQ0TjRvQVFZQUZOeHRISlE0SllDUDRCa2o2d2hjaFl6Nm91QTFRQmVjRm9vOG8yTGtjOVJ4bkZ3V094N3BoUjVkZWhpMUZuYU1lTg?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Increases Share Repurchase Program to $20 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOVzlCZXotZWxkM1ljbENUSlJXOGJJc3dUOXhFUW5zS1d4a0VRVVBuR2RaX2Npc0NVWUFQZDJKLUxyRExMYkpEcDVWSFo3eTRycm5sZTM3ajNscThoMVZpbUxDcjlTbWVUVWd4UFpHTEpVMkpDbEU0VmNNdHRSazRHeVRFMWRiazY2ejJxNGtWYlhzLUNfN211YTZWXzZXaDVreHlKZlZ6UXREZkNpN0wwTDBJVDdZNjlpWDBQQi00NlpiSTNp?oc=5", "source_name": "Business Wire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New $59 Niagen NanoCloud sachets show smoother, more hydrated skin in 2 weeks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRHR2eV9hdTMxcVJQU0pvV1NBOW1JVjloOHJJT2tLakpxR1pQQ1VWMTBtWFFKemNWZk5pTC1OZUs1cEo0UlJHejc4ZmNNbHVhSnJmQmtPcXo1NGx5dXIzUjNPc0cwdi1KUnlJdTFiaU01YUJkc2w5RDlFRnl5RTRFcWNDblF4T3VsZEppWVNjb1lmTDZkLUkyeVBKMUtfSlZLbWEyV0VDQzZjQnIydk9aTmxhbmZSbnRUbWlTZGlSTVc?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Niagen Bioscience (NAGE) Valuation After New 2026 Double Digit Sales Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWEdyc2p1SWEzWW5yaDVMRFhCV3ZSUlNSZ2xITnFvTkxEY2dRd1poOEtmSmR1QzV0clcwd2R5VGxoV1lwUmsyaWFGb1JOR0E0d3RxSHpiZVpyM1c2YWhUb2h6TmdUQnBnTjlBRU1nSm9lQmJELV9tRDMzdW91TTRnRlM3b3d4V0Jabl9B?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Inc. (NAGE) Stock Rises on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxONnlLejFpeno4Zl9kNlJ5TUJELTJPRWZ2MEs2cVpXeHhlWW5sRjdkY2ZuYTEzQWFTaTluOTFrWU44ZkFCZTduUTYtQ0R0WVdYeHJndS1sTnJwb2NER05hcm9PbFA5d0RBUnpCcTN3Sm1pN1NxWHFDa25rVkNLQTE4MHJFMzJPa0tMSGQ0WUFhVGtYbHRNQzFySktPNWNYVk0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Weakness in Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Prove Temporary Given Strong Fundamentals?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNYWpqRFUyazM2YnNkZDNPZzQ2WnNHZUUyekhBVXpNVTY3M0VWcWEwWjZZNHZQbmlIX3lENVBBME1TeUJfV2o2TklUZk5kcGRibG5ibmNycGd1NHd6V2ZieHd6Z1ZzMWI3Rkpub3JtSFBQTEVRSWdfZ2xfSGdCUGxYS0NseHdLVko1XzBn?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAGE Stock Price and Chart \u2014 NASDAQ:NAGE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFByT2o2ZUE3eURaUWVidFhXNUxPWHpYdjZ5cGVZb1M4bjR6SnljeTFTeFduMUg2NnZwWHZWTlJnbUZ4SFFhUUxVWXh6LTUtdGE1YlR5eHpiMGdVMzho?oc=5", "source_name": "TradingView", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Niagen Bioscience (NAGE) to Announce Q2 Financial Results on August 4, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPRTRQdHpHVncyZHdDbUtpLW1NS09BRk40RDl4anBQRUh0OU1OUlZwSWVDN1pFWlF4c0d5M1MtNG1wc0pnUE9pYm5icUFULXJ3RHhWcVY1d2dPdUEzS21EUGxQSVhsOGNEVVFFZFA4SWpwTUVvWGd1cU9CYlMxdkdBalA2S09mb0RkNmIyamliNEk5aDl0X3g4QjNQQV9nemFoY2FuazVLMEhVSVlNQ1JHMQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-21T14:47:43+00:00", "published_display": "21 Jul 2026 14:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience to report Q2 2026 results on August 4", "summary": "Niagen Bioscience, Inc. is scheduled to announce its financial results for the second quarter ending June 30, 2026, on Tuesday, August 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a business update for the company, ", "url": "https://scanx.trade/stock-market-news/companies/niagen-bioscience-to-report-q2-2026-results-on-august-4/46189098", "source_name": "scanx.trade", "published_at": "2026-07-21T14:40:21", "published_display": "21 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Appoints Dr. Abhijit Kale to Lead Global NAD+ Research", "summary": "Niagen Bioscience has appointed Dr. Abhijit Kale as Senior Director of Global External Research to lead its Niagen Research Program. Dr. Kale, with over a decade of experience in aging biology and translational science, will oversee global academic and clinical research collabora", "url": "https://www.latimes.com/b2b/health-life-science/story/2026-07-21/niagen-bioscience-appoints-abhijit-kale", "source_name": "Los Angeles Times", "published_at": "2026-07-21T14:40:20", "published_display": "21 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/niagen-bioscience-report-second-quarter-123200156.html", "source_name": "Business Wire", "published_at": "2026-07-21T12:32:00+00:00", "published_display": "21 Jul 2026 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SteelPeak Wealth LLC Makes New Investment in Niagen Bioscience, Inc. $NAGE", "summary": "SteelPeak Wealth LLC has made a new investment in Niagen Bioscience, Inc. (NASDAQ:NAGE) during the first quarter, acquiring 3,373,000 shares valued at approximately $14.88 million. This new stake represents about 4.24% of the company. Other institutional investors have also adjus", "url": "https://www.marketbeat.com/instant-alerts/filing-steelpeak-wealth-llc-makes-new-investment-in-niagen-bioscience-inc-nage-2026-07-17/", "source_name": "MarketBeat", "published_at": "2026-07-17T10:09:54", "published_display": "17 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research", "summary": "Niagen Bioscience, Inc. has appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will lead the Global Niagen Research Program, overseeing collaborations and shaping the scientific research strategy related to NAD+ biolog", "url": "https://www.businesswire.com/news/home/20260716002772/en/Niagen-Bioscience-Appoints-Abhijit-Kale-Ph.D.-as-Senior-Director-of-Global-External-Research", "source_name": "Business Wire", "published_at": "2026-07-16T21:40:31", "published_display": "16 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)", "summary": "Niagen Bioscience has received both U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168, a novel small molecule therapy for Ataxia Telangiectasia (A-T). These designations highlight the significant", "url": "https://www.businesswire.com/news/home/20260713674314/en/Niagen-Bioscience-Receives-Exclusive-U.S.-FDA-Rare-Pediatric-Disease-RPD-Designation-and-European-Medicines-Agency-Orphan-Medicinal-Product-Designation-OMPD-for-NB4168-for-the-Treatment-of-Ataxia-Telangiectasia-A-T", "source_name": "Business Wire", "published_at": "2026-07-13T12:41:34", "published_display": "13 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience receives FDA, EMA designations for rare disease drug", "summary": "Niagen Bioscience has received Rare Pediatric Disease Designation from the FDA and Orphan Medicinal Product Designation from the EMA for its drug candidate NB4168, which treats Ataxia Telangiectasia. This rare genetic disease currently has no FDA-approved therapies. Despite a 70%", "url": "https://www.investing.com/news/company-news/niagen-bioscience-receives-fda-ema-designations-for-rare-disease-drug-93CH-4788514", "source_name": "Investing.com", "published_at": "2026-07-13T12:41:34", "published_display": "13 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) Stock Looks Reasonable On Earnings Yet Weak On Broader Checks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T23:50:14+00:00", "published_display": "10 Jul 2026 23:50", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience files prospectus to offer common stock up to $50M", "summary": "Niagen Bioscience has filed a prospectus with the SEC to offer and sell up to $50 million in common stock. This move is part of the company's financial strategy to raise capital for future growth, operations, and expansion initiatives. The prospectus details the offering type and", "url": "https://scanx.trade/stock-market-news/ipo/niagen-bioscience-files-prospectus-to-offer-common-stock-up-to-50m/45270726", "source_name": "scanx.trade", "published_at": "2026-07-10T23:40:44", "published_display": "10 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Niagen Bioscience Inc For: 10 July By Investing.com", "summary": "This article reports on the filing of Form 424B5 by Niagen Bioscience Inc. on July 10, 2026. It mentions the company's stock symbol NAGE, which saw a -2.87% change. The content primarily consists of a single sentence announcing the filing, surrounded by numerous navigational link", "url": "https://za.investing.com/news/stock-market-news/form-424b5-niagen-bioscience-inc-for-10-july-93CH-4365025", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T23:10:00", "published_display": "10 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) CFO acquires stock through employee purchase plan", "summary": "Niagen Bioscience's CFO, Pamir Ozan, acquired 4,255 shares of common stock at $2.71 per share through the company's Employee Stock Purchase Plan. This transaction increased Ozan's direct holdings to approximately 11,627 shares, with an additional 2,220 shares indirectly held by t", "url": "https://www.stocktitan.net/sec-filings/NAGE/form-4-niagen-bioscience-inc-insider-trading-activity-4cc4604af45f.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:09:33", "published_display": "09 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital", "summary": "Freedom Capital has upgraded Niagen Bioscience (NASDAQ:NAGE) to a \"strong-buy\" rating, contributing to a mixed analyst sentiment that still results in an average \"Buy\" rating and a consensus price target of $10.50. The stock recently traded down to $3.37, below its moving average", "url": "https://www.marketbeat.com/instant-alerts/niagen-bioscience-nasdaqnage-stock-rating-upgraded-by-freedom-capital-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T16:11:47", "published_display": "09 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026", "summary": "Niagen Bioscience CEO Rob Fried will participate in a virtual fireside chat on July 15, 2026, to discuss the company's recently launched pharmaceutical program for rare genetic diseases and aging-related disorders. The chat will also cover Niagen Bioscience's leadership in NAD+ s", "url": "https://www.businesswire.com/news/home/20260709834448/en/Niagen-Bioscience-CEO-Rob-Fried-to-Participate-in-Virtual-Fireside-Chat-to-Discuss-Pharmaceutical-Strategy-on-July-15-2026", "source_name": "Business Wire", "published_at": "2026-07-09T12:41:10", "published_display": "09 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Niagen Bioscience Inc For: 8 July By Investing.com", "summary": "This article provides details about a Form 4 filing for Niagen Bioscience Inc. on July 8. It indicates that the document is published by Investing.com and was released on July 8, 2026, at 05:22 p.m. The core content highlights the Form 4 filing for NAGE, with a stock performance ", "url": "https://ca.investing.com/news/stock-market-news/form-4-niagen-bioscience-inc-for-8-july-93CH-4726115", "source_name": "Investing.com Canada", "published_at": "2026-07-08T21:40:30", "published_display": "08 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/niagen-bioscience-launches-program-develop-131759130.html", "source_name": "MT Newswires", "published_at": "2026-07-08T13:17:59+00:00", "published_display": "08 Jul 2026 13:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience launches drug candidate for rare disease", "summary": "Niagen Bioscience has announced the launch of NB4168, a drug candidate for Ataxia Telangiectasia (A-T), a rare genetic disease with no FDA-approved therapies. Despite a recent stock decline, the company shows solid fundamentals with a 64% gross profit margin and positive earnings", "url": "https://www.investing.com/news/company-news/niagen-bioscience-launches-drug-candidate-for-rare-disease-93CH-4781634", "source_name": "Investing.com", "published_at": "2026-07-08T13:39:19", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases", "summary": "Niagen Bioscience has launched a pharmaceutical program through its subsidiary, NAD Pharmaceuticals Corp., to develop therapies for accelerated aging and rare genetic diseases. The program's first drug candidate, NB4168, a proprietary NAD+ precursor derivative, will initially tar", "url": "https://www.businesswire.com/news/home/20260708248360/en/Niagen-Bioscience-Launches-Pharmaceutical-Program-for-Accelerated-Aging-and-Rare-Genetic-Diseases", "source_name": "Business Wire", "published_at": "2026-07-08T12:39:19", "published_display": "08 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) CEO adds 1,106 ESPP shares, holds 1.06M directly", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNbVJlRDQtdkZtRkEwMDlzYTNEall6LVNZMjRQYUtfN2ZOaXpOb3NFcVFGUDFOb096WWlOdl84MzJHQXk3Smk4aTc5b2ZhekRpZ1pIVXJPMU9mdU1jT0hlUlZBSFRQbF9FR0pzOHppMGZmdjB5WU1reVE0dWhFdjBvNk1qZjl1ZE45U3Y5MDZQaVFYdTViUXRVN1EyRUNieElRLU41R1g5THFDR2dKYVJaa1U2VlE1Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen pushes NAD+ science into drug development for rare disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNTWNfcWdVUHQ0SlhsZ3pMTWVVM0YySm8wdnVpZGk3aVpuZVdFZHhnQ3FaSmJGTzJKYjhYa1lYc1hfUVFWbVV3eXpDUWtBaTlOcGc0ektoS1RrcnVRbVM0MUZtaFZrVjlUdml0R3huaE5oVWZ2eDB5aDdpaV9LQmNrOXJnREFkY1lKNkNoTmJQdXpZRkIwTlNLUzdIMGxfRHZsTjBHazRaaEhJZkJlVUE2cDJvRHN2Zk8xZ2tYQw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Niagen Bioscience, Inc. \u2013 NASDAQ:NAGE", "summary": "The article title indicates a focus on the Enterprise Value to EBIT forward metric for Niagen Bioscience, Inc. (NASDAQ: NAGE). The content appears to be a stub or a section from a larger financial data platform, providing only the title and navigation/footer information without t", "url": "https://www.tradingview.com/symbols/NASDAQ-NAGE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T22:42:05", "published_display": "06 Jul 2026 22:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) SVP, General Counsel acquires 2,314 ESPP shares", "summary": "Niagen Bioscience's SVP and General Counsel, Carlos Luis Lopez, acquired 2,314 common shares at $2.71 each through the company's Employee Stock Purchase Plan (ESPP). This transaction, exempt under SEC Rules 16b-3(c) and 16b-3(d), increased his direct ownership to 4,565 shares. Th", "url": "https://www.stocktitan.net/sec-filings/NAGE/form-4-niagen-bioscience-inc-insider-trading-activity-6d5c51419df5.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:04", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freedom Broker initiates Niagen Bioscience stock coverage with buy rating", "summary": "Freedom Broker has initiated coverage on Niagen Bioscience Inc. (NASDAQ:NAGE) with a Buy rating and a $9.00 price target, highlighting significant upside potential given its current trading price of $3.49 against an analyst consensus of $10-$18. The firm's investment thesis is su", "url": "https://www.investing.com/news/analyst-ratings/freedom-broker-initiates-niagen-bioscience-stock-coverage-with-buy-rating-93CH-4777300", "source_name": "Investing.com", "published_at": "2026-07-06T20:12:15", "published_display": "06 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freedom Broker initiates Niagen Bioscience stock coverage with buy rating By Investing.com", "summary": "Freedom Broker has initiated coverage on Niagen Bioscience Inc. (NASDAQ:NAGE) with a Buy rating and a price target of $9.00, citing significant upside potential from its current trading price of $3.49. The firm's investment thesis is based on secular tailwinds in the longevity ec", "url": "https://ca.investing.com/news/stock-market-news/freedom-broker-initiates-niagen-bioscience-stock-coverage-with-buy-rating-93CH-4721491", "source_name": "Investing.com Canada", "published_at": "2026-07-06T19:42:05", "published_display": "06 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Implied Volatility Surging for Niagen Bioscience Stock Options", "summary": "Implied volatility for Niagen Bioscience (NAGE) stock options is surging, particularly for the August 21, 2026 $12.50 Call, indicating that the market expects significant price movement. Despite this, analysts currently rate NAGE as a Zacks Rank #3 (Hold), with recent downward re", "url": "https://www.tradingview.com/news/zacks:26468dc52094b:0-implied-volatility-surging-for-niagen-bioscience-stock-options/", "source_name": "TradingView", "published_at": "2026-07-06T15:41:32", "published_display": "06 Jul 2026 15:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAGE - Niagen Bioscience Inc Options", "summary": "This page provides a detailed financial overview of Niagen Bioscience Inc (NAGE), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key metrics such as P/E, EPS, insider and institutional ownership, profitabi", "url": "https://finviz.com/stock?t=NAGE&p=d&ty=oc&r=m6&e=2026-07-17&ov=list_date", "source_name": "Finviz", "published_at": "2026-07-05T17:41:32", "published_display": "05 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Niagen Bioscience, Inc (NAGE)", "summary": "This article analyzes the historical performance of investing $1,000 in Niagen Bioscience, Inc. (NAGE) over different periods. It provides an overview of Niagen Bioscience, detailing its focus on NAD+ science and healthy-aging research through patented ingredients like Niagen\u00ae, c", "url": "https://www.stocktitan.net/tools/stock-return-calculator/NAGE", "source_name": "Stock Titan", "published_at": "2026-07-05T05:42:05", "published_display": "05 Jul 2026 05:42", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Niagen Bioscience stock rating on patent ruling By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and an $11.00 price target for Niagen Bioscience (NASDAQ: NAGE) following a favorable patent ruling. The U.S. District Court for the District of Delaware upheld the enforceability of a patent related to crystalline nicotinamide riboside", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-niagen-bioscience-stock-rating-on-patent-ruling-93CH-4715938", "source_name": "Investing.com Canada", "published_at": "2026-07-01T11:39:37", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Niagen Bioscience Inc For: 29 June By Investing.com", "summary": "This article announces that Investing.com has published information regarding the Form S-3 filing by Niagen Bioscience Inc for June 29. The brief notice highlights the filing and its publication date. It also provides current stock market data for various indices, commodities, an", "url": "https://ng.investing.com/news/stock-market-news/form-s3-niagen-bioscience-inc-for-29-june-93CH-2577409", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T03:40:24", "published_display": "30 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Niagen Bioscience Inc For: 26 June By Investing.com", "summary": "This article provides an Investing.com report on the Form 4 filing for Niagen Bioscience Inc., dated June 26. It includes standard disclaimers about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing that the provided data may not be re", "url": "https://m.au.investing.com/news/stock-market-news/form-4-niagen-bioscience-inc-for-26-june-93CH-4507476?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-27T01:39:16", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) director granted 31,746 stock options at $3.45", "summary": "Niagen Bioscience (NAGE) director Patrick Kristin was granted 31,746 stock options with an exercise price of $3.45 per share. These options will vest 100% on June 24, 2027, and have an expiration date of June 23, 2036. This transaction is classified as an equity compensation awar", "url": "https://www.stocktitan.net/sec-filings/NAGE/form-4-niagen-bioscience-inc-insider-trading-activity-a9625be28c13.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:10:21", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Steven D. Rubin receives 31,746 Niagen Bioscience (NAGE) stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOb1hFeFlKakJnXzN5UmV3YS1zMGlCVEFCUks4NHpUVjkwUGdQSnJTVkhsbURWTGtCZDd6ZjNIVlM0UV8yaHlMNVNCZzVUeVQ0Wml3aV9nOEtydDRGdU1xZC1wRjF3Z2tqN0gxMjI4NlZFZzUySFVuNWppOVBaXy1vbXFVeFlyM0ViTTJzSXVwWVBsVUh4S3dlZV9xR193bWtiTm9hTEQ3Sm55ek5aTjc2eGowSFUzUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) director receives 31,746-share stock option grant at $3.45", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOTE5Rb1hCclZ4dFQ3SGxzbTkzMnNEVnBOTUhTVEpjaTBmaHpSNG02RkJkNjdVN2JVWHJLMzYydFhWMUFXVmczSkF3Ujh4NWFsNkRIbktqOTVsTVB6ZnhWLXBlelQ2V3J3TlVSM2Q3Vk9kazJJSTh4Ym5RVTQzeVcyVVJYUmhKbW5FejFOYTlRckZ2UEpQRy1WaDNpVEQyYl9nZnNFOGxrdFhMcVlrNXA3WDY0VFM5UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/niagen-bioscience-inc-nage-renames-182049027.html", "source_name": "Insider Monkey", "published_at": "2026-06-19T18:20:49+00:00", "published_display": "19 Jun 2026 18:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience And 2 Other Promising Penny Stocks To Watch", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNVjQzYU45Qnl0b3Nub2JOVy0wRmlaejRXNHFETTB2andLSjhhZzAteXAwaUJUenpjODVoMnBycGdaSW5yeWdxLUJPd185NTRGVGpXUkZUX1VWWVlJTkxZNDJWVTVCMHVjZTM0bFpkZkRiSlJXYUoxcnpqOV9KdWpHRy1FcTlzV0ZWMFlRd3lLeDluLXpfQTZIUDlmdjM4T3hfX0pmOXVXenctd1E?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Niagen's program backing 300+ NAD+ research collaborations", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOWUpvZzNwQUhJNnlQVGJCNU5tdl9DWDNOY2Z1M1pqTjZ0ZmNoR2IwMTUxMmFOWlc5NXF4R0lxN2FpdlJQRGR5TVhIVFhJQjk5cDk5RFJVQTFBMDF4d054NmlNU29BekVXQVRHeG9DNEdJVG50YnY1OHhlSTBuaWw4eTNiWjduNzV1S2RiMGZCWVdiZ2xWMFplU1lSUTg4Mkhrb25RdVUycER0TUxIRFhaa1Mtd0lMbHJIMGhveg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPcDM0YmxQaWdQTWhVbGtNWnFxZzZySl9mMG8yNDJ0bklZdUpud1E1cEZzZ24yanphcllacThQUEVuTVlhZVBjaDhSME1aSkhEX1ktbVRNYVR2bG4wdHpWTGxldXlIdVJmeWJpWEJmX0ZUYXlPMU5wTURObllDSXhqNzB4ZFFLczhaQ2VZczdBZURKQjNRSjZxMUtEWHM5ODdPRkJONQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYVlablRJTEw5Uy1DOW5pUjlzSkhqOEtESVYtZkxPRHktb2FoQU5KdDFkZVBIOUtJR3pfUUxpNFYwUjdEcURXWTlDNEJhdHBnamp1VFhvV1p4cUJYcWlFemVNblpsQzl5YzFRWFY2V3ZVbGRubEstbXN4d2k5eWs1aUxhekFqRW5wcWR0emh2b25qaVJhd0NnWmpJSlpuUmhlb2tFUGN4ODBfSEU?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQLVFZMkZkNVgwcmhXNXJkZFBzcDZOWVpKQ2pveTRabDJSX1Z5MWpFTzRYaFlISXJ6QjZVTWpUTi14OVYycVdGY3F0a2loUmctZTZwM2NKX0lsMDBjeFptenV5Nm4wQjVGckFPNlFLdGhWdk1aZkY3bmpQRjBfcS1xbWtYQ3ljRUcyejNVemZEQzFnOWRFT1lMVnRxNkJPamZuYm54SnF3?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcDExT0lHVnhRTjNQT0pGTWxLNHJXc1hzdjdHVVZ4NWp2TzZMWjhVeXhqY0loWHZyUW1STlh1X0w5Y3pwaVZkWnc5VXlfM0ZOOThJeko3cVJqaUFkWjRvRlRieVhyeS12Ym9HNVpYS0NKajAxcEwtNFZYZXBkSmVFbS0yc1FWUE5CRGp5Z2FQNVVGZzFOcGRnZXlZcVVTaXQ1OHhQR2RQb2pZcGZfRTRqSDVSM0xHNGhCWHphdHdwZ091WGNmWkkyVjVKOWdGQi16cWVqOTg5Uzkya2dIa3c?oc=5", "source_name": "Business Wire", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZWkwc2s3RTBzemNHT3VmakR3Ukdwd1FQRlhpU2M2Y3B2RFVsbHJnV0s2dTJkQ2x2WjA5WXFwblpkS1RzYjN4U3UzSVNGV2JGTlZGUjI4RGtBLUxQNTZaMGdFNkt5V0lrd05tekpzMVdLQ191bHRfYkoxR3ZMNzBwOGZla2w1dGRYVHU4RmlJaE9wUHVlMldyNFFGM2VPaWdjelFicVB1XzM?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Inc. (NAGE): Among the 12 Cheap Penny Stocks to Invest In Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPZFdZVkc0NzlhRjQ5TG9Ma0xJN0VxTW1sRG9pdzFXNjR2a3Zid3hsRHdIZTlYalBnU0tTalBUOU9WSTFwSTFDNWVMdXpiN3hseVg5dVQ3dkJLRjhLdlhNbTJGZ05TWm96OFJhUzlWMXdqcnRSUjJTSXpoVVMxZ2hNamRWLXhORlJBcThUUlZuX3EyN21Dd1dxWWV4SFBvQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Niagen Bioscience (NAGE) Story Is Shifting Around Price Targets And Injectables Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxORUFuOHdjVDU1cklMb3BWTGNDd3hqQnp5YURjVmVOMXlQVm14N1U5cldfdUt1MEtTVTZBcTNBZHBqS0JQdnp5UVNicUtXWW1aQmtVb2RGaVpQUEQ0TjRvQVFZQUZOeHRISlE0SllDUDRCa2o2d2hjaFl6Nm91QTFRQmVjRm9vOG8yTGtjOVJ4bkZ3V094N3BoUjVkZWhpMUZuYU1lTg?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Increases Share Repurchase Program to $20 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOVzlCZXotZWxkM1ljbENUSlJXOGJJc3dUOXhFUW5zS1d4a0VRVVBuR2RaX2Npc0NVWUFQZDJKLUxyRExMYkpEcDVWSFo3eTRycm5sZTM3ajNscThoMVZpbUxDcjlTbWVUVWd4UFpHTEpVMkpDbEU0VmNNdHRSazRHeVRFMWRiazY2ejJxNGtWYlhzLUNfN211YTZWXzZXaDVreHlKZlZ6UXREZkNpN0wwTDBJVDdZNjlpWDBQQi00NlpiSTNp?oc=5", "source_name": "Business Wire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New $59 Niagen NanoCloud sachets show smoother, more hydrated skin in 2 weeks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRHR2eV9hdTMxcVJQU0pvV1NBOW1JVjloOHJJT2tLakpxR1pQQ1VWMTBtWFFKemNWZk5pTC1OZUs1cEo0UlJHejc4ZmNNbHVhSnJmQmtPcXo1NGx5dXIzUjNPc0cwdi1KUnlJdTFiaU01YUJkc2w5RDlFRnl5RTRFcWNDblF4T3VsZEppWVNjb1lmTDZkLUkyeVBKMUtfSlZLbWEyV0VDQzZjQnIydk9aTmxhbmZSbnRUbWlTZGlSTVc?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Niagen Bioscience (NAGE) Valuation After New 2026 Double Digit Sales Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWEdyc2p1SWEzWW5yaDVMRFhCV3ZSUlNSZ2xITnFvTkxEY2dRd1poOEtmSmR1QzV0clcwd2R5VGxoV1lwUmsyaWFGb1JOR0E0d3RxSHpiZVpyM1c2YWhUb2h6TmdUQnBnTjlBRU1nSm9lQmJELV9tRDMzdW91TTRnRlM3b3d4V0Jabl9B?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience Inc. (NAGE) Stock Rises on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxONnlLejFpeno4Zl9kNlJ5TUJELTJPRWZ2MEs2cVpXeHhlWW5sRjdkY2ZuYTEzQWFTaTluOTFrWU44ZkFCZTduUTYtQ0R0WVdYeHJndS1sTnJwb2NER05hcm9PbFA5d0RBUnpCcTN3Sm1pN1NxWHFDa25rVkNLQTE4MHJFMzJPa0tMSGQ0WUFhVGtYbHRNQzFySktPNWNYVk0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Weakness in Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Prove Temporary Given Strong Fundamentals?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNYWpqRFUyazM2YnNkZDNPZzQ2WnNHZUUyekhBVXpNVTY3M0VWcWEwWjZZNHZQbmlIX3lENVBBME1TeUJfV2o2TklUZk5kcGRibG5ibmNycGd1NHd6V2ZieHd6Z1ZzMWI3Rkpub3JtSFBQTEVRSWdfZ2xfSGdCUGxYS0NseHdLVko1XzBn?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAGE Stock Price and Chart \u2014 NASDAQ:NAGE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFByT2o2ZUE3eURaUWVidFhXNUxPWHpYdjZ5cGVZb1M4bjR6SnljeTFTeFduMUg2NnZwWHZWTlJnbUZ4SFFhUUxVWXh6LTUtdGE1YlR5eHpiMGdVMzho?oc=5", "source_name": "TradingView", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQU2k5UzZoc1RrMVd0RXREUjd3dWlpNS10bGpqUFRRMVVoN1ZuOWoteVJaZ05xNV9FV2JaSTVjM2JsdGQ5SWJwdWh3RWtpUFVGSHZUWUdObjU2WnNiZWJsNkIxVi11em5YSFQ0bjVIUTM4X3ZkeXlMbDNmRWpsTlJTbk5uYk1WdW5ZMmp4R2xYTnN2N0RyaUFXRVdrUzVLd0pSdktwLTFsdjRlUFRFeGlkbjFhTDNqbHVaOEt2ZUVWaWtuQjVGdXdid3V3Z3ZqTjMwek5sR185eExDZG10anF5d0dpY3JYQdIB6wFBVV95cUxNMElfOHF1aVF0c2ItOFhBVUd3ejdyZnZyNmdsMWl2ekpfRDhkT0FRdFpBZU1DMjE1dnpHbjM3MUp5R080czZNZEh0UTFIV3FVb1VPWGFHVXoxaDB0LXc5aXIyRllxOUZUMjZ1aTJJVE1zTm5ITXJnb2tsTUtYNFZqc1A2cFcxRjRRYlphWnI4TlJTckhuNG1FUlM3UE1KT3NWamd1SnRyYUpFUVp2UUdfV2U2Nm55NGJyX3F2ZUFBaUo5UHhqWE9BVXNnRFZVYXhWenpFVFhFemRaSFNYbnJjM0lJSVRKUHVuaVFF?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 64, "sentiment_summary": {"positive": 15, "negative": 5, "neutral": 44, "score": 55, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.15, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 9.76, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 3.28, "latest_week": "2026-07-17", "one_week_move": -3.2, "four_week_move": -6.3, "twelve_week_move": -33.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.109119, "market_dynamics_buy_signal": false, "relative_strength": -53.122196, "fair_value_gap": -34.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.6952, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.2% over one week, -6.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "Stock Titan", "count": 10}, {"label": "Business Wire", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Investing.com Canada", "count": 3}, {"label": "scanx.trade", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 5}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.2% over one week, -6.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Niagen Bioscience (NAGE) to Announce Q2 Financial Results on August 4, 2026"}], "updated_at": "2026-07-23T08:48:28.088830+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}